Qijun Yang

Qijun Yang

Auto-generated profile, based on publicly available information

Qijun Yang

Lerner Research Institute, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Hepatology Communications
Verified
Journal Article
Open access
SSShreya Sengupta
Shreya Sengupta
AAAkhil Anand
Akhil Anand
QYQijun Yang
Qijun Yang
MRMeghan Reagan
Meghan Reagan
MHMariah Husted
Mariah Husted
JMJessica L. Mellinger
Jessica L. Mellinger
Background: We analyzed early outcomes regarding the impact of our integrated alcohol-associated liver disease (ALD) clinic on patients with ALD and alcohol use. Methods: We conducted a retrospective study of patients with ALD who were evaluated in our integrated clinic from May 1, 2022, to December 31, 2023. Primary outcomes included differences in baseline clinical/demographic data between patients who accepted versus declined an appointment and changes in the severity of ALD, alcohol consumption, functional status, hospital utilization, and remission in alcohol use disorder for evaluated patients. Results: Patients who declined appointments (n=66) had higher median no-show rates (15.0 [8.0,30.0] vs. 8.5 [3.25,15.0], p <0.001), social vulnerability index (0.53 [0.26,0.79] vs. 0.38 [0.17,0.63], p =0.033), and proportions of cirrhosis (78.8% vs. 59.8%, p =0.017) versus evaluated patients. Comparison of baseline to first follow-up visit for evaluated patients (n=102) demonstrated significant reductions in median AST (59.5 [41.75, 89] vs. 44.5 [33.5, 56.25], p <0.001), alanine-aminotransferase (33.5 [20,45.25] vs. 26.5 [18.75,33.0], p =0.017), total bilirubin (1.6 [0.7,3.3] vs. 1 [0.5,1.9], p= 0.001), phosphatidylethanol (263 [35, 784] vs. 0 [0, 163], p <0.001), MELD-3.0 and Sodium scores for patients with alcohol-associated hepatitis and cirrhosis (16 [11, 18.75] vs. 12 [9, 14], p <0.001), 14 [9.25, 17.75] vs. 11 [8.5, 14], p <0.001), and Child-Turcotte-Pugh scores for patients with cirrhosis (9 [6, 10.5] vs. 7 [6, 9], p <0.001). The proportion of patients with active-severe alcohol use disorder significantly decreased (85.2% vs. 51.9%, p <0.001). Additionally, patients had significant reductions in emergency department utilization (incidence rate ratio of 0.64 emergency department visits/month ( p =0.002) and 0.71 hospital admissions/month ( p =0.025). However, after considering the false discovery rate, the reduction in hospitalization admissions/month was not statistically significant (False Discovery Rate adjusted p =0.056). Conclusions: Our integrated approach led to reductions in liver injury, degree of liver decompensation, alcohol use, and ED utilization, and remission in AUD in a population of both non-transplant ALD and post-transplant patients.

22 August 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ACArjun Chatterjee
Arjun Chatterjee
ASAmandeep Singh
Amandeep Singh
RTRaj Jessica Thomas
Raj Jessica Thomas
RPRenan Prado
Renan Prado
RKRidhima Kaul
Ridhima Kaul
PCPrabhleen Chahal
Prabhleen Chahal
INTRODUCTION: Fatty pancreas disease (FPD), marked by excess fat within the pancreas, is often incidentally detected on imaging. Despite recognized metabolic links, its clinical significance remains unclear. More granular data from large, well-characterized US cohorts are needed to clarify its relevance. This study quantified intrapancreatic fat deposition and assess its natural history and related outcomes. METHODS: Adults 18 years and older with radiologically confirmed FPD between 2004 and 2024 were identified from institutional databases. Controls without FPD were matched 1:2 by age, sex, body mass index, and smoking status. Patients with excessive alcohol intake, previous pancreatitis, pancreatic cancer, surgery, cystic fibrosis, or prolonged steroid/antiviral use were excluded. Fat content in the pancreas and liver, as well as subcutaneous and visceral fat areas, were measured using iNtuition software on noncontrast computed tomography scans. RESULTS: We included 82 FPD patients and 164 matched controls (median age 65 years; 55% women; median body mass index 32). Subcutaneous and hepatic fat were similar between groups, but intrapancreatic fat deposition was markedly higher in FPD patients (26.8% vs 4.9%, P < 0.001). Over a mean 4-year follow-up, FPD patients had significantly higher rates of acute pancreatitis (12% vs 1.2%, P < 0.001), chronic pancreatitis (6.1% vs 0.6%, P = 0.017), pancreatic cysts (34.1% vs 4.9%, P < 0.001), and pancreatic cancer (1.6% vs 0%, P = 0.012). Extrapancreatic cancer incidence did not differ. DISCUSSION: FPD is associated with an increased risk of pancreatic cancer, acute pancreatitis, chronic pancreatitis, and incidental pancreatic cysts, independent of obesity or hepatic steatosis, suggesting a potentially causative role of FPD in the pathogenesis of exocrine pancreatic diseases.

15 July 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
RSRavi S. Shah
Ravi S. Shah
JHJessica H. Hu
Jessica H. Hu
SBSalam Bachour
Salam Bachour
AJAbel Joseph
Abel Joseph
HSHareem Syed
Hareem Syed
BCBenjamin H. Click
Benjamin H. Click
INTRODUCTION: Following ileocolic resection (ICR), the clinical importance and prognostic implications of histologic activity on biopsies in Crohn's disease (CD) patients with endoscopic remission are not well defined. The aim of this study was to determine if histologic activity in patients with endoscopic remission is associated with future risk of endoscopic and/or radiologic postoperative recurrence (POR). METHODS: In this multicenter retrospective cohort study, adult patients with CD who underwent ICR between 2009 and 2020 with endoscopic biopsies of ileal mucosa from Rutgeerts i0 on index colonoscopy were included. The composite rate of endoscopic (Rutgeerts score ≥i2b) and radiologic (active inflammation on imaging) recurrence was compared in patients with and without histologic activity using a Kaplan-Meier survival analysis. A multivariable Cox proportional hazard regression model including clinically relevant risk factors of POR, postoperative biologic prophylaxis, and histology activity was designed. RESULTS: A total of 113 patients with i0 disease on index colonoscopy after ICR were included. Of these, 42% had histologic activity. Time to POR was significantly earlier in the histologically active versus normal group (P = 0.04). After adjusting for clinical risk factors of POR, histologic activity (HR 2.37, 95% CI 1.17–4.79; P = 0.02) and active smoking (HR 2.54, 95% CI 1.02–6.33; P = 0.05) were independently associated with subsequent composite POR risk. DISCUSSION: In patients with postoperative CD, histologic activity despite complete endoscopic remission is associated with composite, endoscopic, and radiographic recurrence. Further understanding of the role of histologic activity in patients with Rutgeerts i0 disease may provide a novel target to reduce disease recurrence in this population.

5 June 2025 in Obesity Surgery
Verified
Journal Article
Open access
PDF file
BEBaila Elkin
Baila Elkin
JDJoseph El Dahdah
Joseph El Dahdah
QYQijun Yang
Qijun Yang
YWYueqi Wu
Yueqi Wu
JMJohn McMichael
John McMichael
CRCarol Rouphael
Carol Rouphael
Background: The role of routine esophagogastroduodenoscopy (EGD) before metabolic bariatric surgery (MBS) remains unclear. We examined which patients were more likely to undergo preoperative EGD with biopsies, assessed the prevalence of clinically significant gastric pathologies on surgical specimens that may have been missed preoperatively, and analyzed patient factors associated with those findings. Methods: Patients ≥ 18 years old with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) between 2018 and 2022 were included. Demographic, clinical, endoscopic, and pathology (from EGD and surgical specimens) characteristics were collected. Descriptive statistics were used. Uni- and multivariable Cox regression analyses assessed factors associated with clinically significant endoscopic and pathology findings. Results: Of 3718 patients (38.8% RYGB, 61.2% SG), 80% were female, 69.9% White, and 12.6% Hispanic. Median age at surgery was 45.7 years; median body mass index was 44.5 kg/m2. Preoperative EGD was performed in 36.9% of patients. Surgical specimens were available for 2349 patients (2273 SG and 76 RYGB), among whom 135 had clinically significant pathology. 63.7% of these patients had no preoperative EGD, 15.6% had preoperative EGD without biopsies, and 20.7% preoperative EGD with biopsies. Older age and non-White, non-Black race were associated with clinically significant findings on EGD or pathology. Conclusions: Several clinically relevant gastric pathologies could have been detected preoperatively via EGD with biopsies, yet about two-thirds did not undergo this evaluation. Older age and non-White, non-Black race were associated with these findings. Further research is needed to assess predictive factors of significant findings and cost-effectiveness of routine versus selective pre-operative EGD.

28 August 2025 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
SGSamita Garg
Samita Garg
DHDin Hoxha
Din Hoxha
DLDavid Long
David Long
SVSara Valencia
Sara Valencia
QYQijun Yang
Qijun Yang
DCDian-Jung Chiang
Dian-Jung Chiang
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. Although they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aimed to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenomas and sessile serrated polyp (SSP) detection. METHODS: We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at a tertiary academic medical center. Adults who used a GLP-1RA within 1 week of their colonoscopy formed the treatment group; patients not on GLP-1RA (nonusers) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, sex, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use. RESULTS: Among 49,987 patients (4,269 GLP-1RA users, 45,718 nonusers), GLP-1RA use was associated with increased odds of inadequate bowel preparation (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.04–1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59–2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57–0.89). DISCUSSION: GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection was unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.

20 April 2026 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
MCMichael Cymbal
Michael Cymbal
RPRenan Prado
Renan Prado
Leandro Luis Sierra CarreroLeandro Luis Sierra Carrero
Leandro Luis Sierra Carrero
ACArjun Chatterjee
Arjun Chatterjee
SFStephen A. Firkins
Stephen A. Firkins
RSRoberto Simons-Linares
Roberto Simons-Linares
Sleeve gastrectomy (SG) is the most commonly performed bariatric procedure in the United States, but it is associated with an increased risk of de novo or worsened gastroesophageal reflux disease (GERD). Conversion to Roux-en-Y gastric bypass (RYGB) is considered the gold standard for treating refractory GERD after SG, though objective outcomes remain under-reported. To evaluate the efficacy of conversion from SG to RYGB for medically refractory GERD using objective measures of improvement. Secondary objectives included assessing whether weight loss, additional anatomic repairs, or application of updated American College of Gastroenterology (ACG) GERD diagnostic criteria impacted outcomes. Academic tertiary care center (Cleveland Clinic Foundation, Cleveland, Ohio, United States). A retrospective cohort study was conducted on patients who underwent SG followed by RYGB for refractory GERD from July 2004 to August 2024. GERD improvement was defined as decreased use of proton pump inhibitors (PPIs), endoscopic, or pH testing improvement. Logistic regression and chi-square analyses were used to assess predictors of improvement. Of 117 patients, 53 (45.3%) showed objective GERD improvement post-RYGB. Most improved via reduction in PPI omeprazole equivalence (88.7%), of which 35.8% discontinued PPIs completely. Neither total body weight loss (P = .257) nor concurrent anatomical repairs (P = .615) correlated with GERD improvement. Meeting new ACG GERD diagnostic criteria was significantly associated with improvement (63.6% vs 33.3%, P = .03). Conversion to RYGB results in objective GERD improvement in nearly half of patients undergoing conversion, independent of weight loss or anatomical repairs. ACG diagnostic criteria may help predict which patients benefit most. Prospective studies are needed to validate findings and refine surgical decision-making.